The CR3 research group investigates how age-associated metabolic and genomic instability drive cancer and metabolic diseases, with the goal of enabling precision therapeutic intervention. Using single-cell and spatial multi-omics, the group maps aging trajectories of metabolic–genomic instability and builds integrated databases to identify stage-specific metabolic vulnerabilities and key regulatory factors. Leveraging large-scale patient cohorts, CR3 elucidates links between aging, metabolic dysregulation, and cancer subtypes, and discovers actionable biomarkers and drug targets. By developing novel therapeutic modalities and nano-enabled delivery platforms, the group advances patient-specific metabolic reprogramming strategies toward translational and clinical application.